HIV

Gene editing shows promise in combating HIV reservoirs
Gene editing shows promise in combating HIV reservoirs
Fierce Biotech
gene editing
HIV
Flag link:
Gilead: Did Biktarvy Kill The Sell Thesis?
Gilead: Did Biktarvy Kill The Sell Thesis?
Seeking Alpha
Gilead Sciences
Biktarvy
HIV
Kite Pharma
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
GSK's two-drug HIV regimen wins European panel approval
GSK's two-drug HIV regimen wins European panel approval
Reuters
GSK
HIV
Europe
CHMP
Juluca
Flag link:
Gilead Sciences' $14 Billion-Per-Year Threat
Gilead Sciences' $14 Billion-Per-Year Threat
Motley Fool
Gilead Sciences
GS-9620
GS-9722
HIV
Flag link:
Is Gilead Sciences Trying to Put Itself Out of Business?
Is Gilead Sciences Trying to Put Itself Out of Business?
Motley Fool
Gilead Sciences
hepatitis C
HIV
GS-9620
PGT121
Flag link:
Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys
Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys
Endpoints
HIV
Gilead Sciences
R&D
Flag link:
How Huge Is the Latest HIV Drug Approval for Gilead Sciences?
How Huge Is the Latest HIV Drug Approval for Gilead Sciences?
Motley Fool
Gilead Sciences
HIV
FDA
Biktarvy
Flag link:
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
No more Mr Nice Guy: GlaxoSmithKline is coming out of its corner swinging
Endpoints
GSK
R&D
Pharma CEOs
Emma Walmsley
Advair
Novartis
Sandoz
Gilead Sciences
HIV
Flag link:
A new pill to treat HIV just got approved — and it could shake up a $22 billion market
A new pill to treat HIV just got approved — and it could shake up a $22 billion market
Business Insider
HIV
Gilead Sciences
FDA
Bictegravir/emtricitabine/tenofovir alafenamide
Flag link:
Ready to take on Glaxo, Gilead's combo HIV med Biktarvy wins $6B FDA nod
Ready to take on Glaxo, Gilead's combo HIV med Biktarvy wins $6B FDA nod
Fierce Pharma
GSK
Gilead Sciences
HIV
FDA
Biktarvy
Flag link:
Aetna to pay $17 million over mailing that revealed HIV meds
Aetna to pay $17 million over mailing that revealed HIV meds
Stat
Aetna
HIV
patients
privacy
Flag link:
5 Ways Gilead Sciences Plans to Return to Growth
5 Ways Gilead Sciences Plans to Return to Growth
Motley Fool
Gilead Sciences
HIV
liver disease
cell therapy
inflammation
M&A
Flag link:
Teva rolls out exclusive generic of Gilead's Viread at the end of an awful week
Teva rolls out exclusive generic of Gilead's Viread at the end of an awful week
Fierce Pharma
Teva Pharmaceutical
Gilead Sciences
Viread
hepatitis B
HIV
antivirals
Flag link:
Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches
Why Gilead Could Have 'Greatest' Ever In HIV Drug Launches
Investors Business Daily
Gilead Sciences
drug launches
HIV
bictegravir
Flag link:
J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine
J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine
Endpoints
JNJ
HIV
vaccines
R&D
mosaic vaccine
Imbokodo
HVTN 705/HPX2008
Flag link:
Fresh off its Juluca approval, GlaxoSmithKline beefs up trials of long-acting HIV duo
Fresh off its Juluca approval, GlaxoSmithKline beefs up trials of long-acting HIV duo
Fierce Pharma
GSK
cabotegravir
HIV
Endurant
ViiV
JNJ
Janssen
Flag link:
J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space
J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space
Yahoo/Zacks.com
JNJ
GSK
Jucala
HIV
Flag link:
With billions riding on their success, GSK bags quick OK for its two-drug HIV combo Juluca
With billions riding on their success, GSK bags quick OK for its two-drug HIV combo Juluca
Endpoints
GSK
HIV
Juluca
ViiV
Flag link:
GSK and Gilead go head to head as HIV drugs enter new phase
GSK and Gilead go head to head as HIV drugs enter new phase
Reuters
GSK
Gilead Sciences
HIV
Dolutegravir
bictegravir
Flag link:

Pages